**Supplementary Table S2. Detailed inclusion and exclusion criteria for the clinical trial (NCT04370405)**

|  |
| --- |
| **Inclusion criteria** |
| 1. Voluntarily participating in this clinical trial, understanding the study procedures, and capable of signing an informed consent form in writing; 2. Grade 0-2 ECOG performance status (PS); 3. Expected survival ≥ 3 months; 4. Having at least one measurable disease conforming to IRWG criteria; 5. Good organ function level: 6. ANC ≥ 1.0 × 109/L; 7. PLT ≥ 70 × 109/L (≥ 50 × 109/L for patients with marrow involvement); 8. Hb ≥ 80 g/L (≥ 70 g/L for patients with marrow involvement); 9. TBIL ≤ 1.5 × ULN; 10. ALT and AST ≤ 2.5 × ULN; 11. BUN/Urea and Cr ≤ 1.5 × ULN; 12. LVEF ≥ 50%; 13. Corrected QT interval by Fridericia method (QTcF) < 450 ms for males and < 470 ms for females. 14. Not participated in a clinical trial as a subject within 1 month before the present trial; 15. Capable of following the trial protocol in the investigator’s opinion. |
| **Exclusion criteria** |
| 1. Pleural effusion or ascites that cannot be controlled by drainage or other methods; 2. Various factors affecting drug administration and absorption, such as inability to swallow, chronic diarrhea or intestinal obstruction; 3. For patients who are receiving treatment with medication that may lead to a prolonged QT interval (such as antiarrhythmic drugs), the treatment cannot be discontinued or switched to a different medication prior to starting study drug; 4. Tumor with central nervous system (CNS) invasion; 5. Any cardiac disorders including (1) angina; (2) arrhythmia requiring clinical treatment and intervention; (3) myocardial infarction; (4) cardiac failure; (5) any other cardiac disorders which cause the patients unsuitable to be enrolled in this trial in the investigator’s opinion; 6. Female in gestation period or lactation period, or female with childbearing potential who has positive baseline pregnancy test result; 7. Severe concomitant diseases (e.g. severe hypertension, diabetes, thyroid disorder, etc.) that compromise the safety of patients or prevent patients from completing the study in the investigator’s opinion; 8. Other neoplasm malignancy within the past 5 years, except cured skin basal cell carcinoma and cervix carcinoma in situ; 9. Receipt of an attenuated live vaccine within 30 days before the first dose. |